about
XRCC1 is required for DNA single-strand break repair in human cells.Multifunctional upconversion-magnetic hybrid nanostructured materials: synthesis and bioapplicationsBrain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium.Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing ProjectsGenetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Methylenetetrahydrofolate reductase C677T and overall survival in pediatric acute lymphoblastic leukemia: a systematic review.Role of the MTHFR polymorphisms in cancer risk modification and treatment.Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?Pharmacogenomics: road to anticancer therapeutics nirvana?Pharmacogenetic candidate genes for melanoma.Pharmacogenomics and breast cancer.Personalised medicine for cancer: from drug development into clinical practice.Sarcomas and pharmacogenetics.Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.Therapeutic drug monitoring of cancer chemotherapy.Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy.Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Methods for optimizing statistical analyses in pharmacogenomics researchXRCC1 Arg399Gln polymorphism contributes to increased risk of colorectal cancer in Chinese population.Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.XRCC1 R399Q polymorphism and risk of normal tissue injury after radiotherapy in breast cancer patients.Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.Lab on upconversion nanoparticles: optical properties and applications engineering via designed nanostructure.Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status.Pharmacogenetic And Tumour Drugs.
P2860
Q24796404-1546369C-77BD-4362-960D-BB32819281C7Q26863494-64062300-52B3-4D02-B498-15234EE83E3FQ30481789-37078A8F-704A-4508-8CC0-2CD977AB7475Q33530851-1600A2C3-BE52-4E31-A7DC-F3121D963746Q33879736-1DEF892C-2AB4-4F05-B76E-6DAA4CE4F38FQ34336668-A145C27D-18FD-44D4-9B9A-429254C78A1BQ34658549-AC0CB9DA-3B5E-4E03-A3A9-8D6C397DF3B0Q34847802-650FF308-DFE6-4ABB-967C-8F236D07D6AFQ35551155-4C9DBAF5-76C1-4ACE-A9B9-33DA5D8B1B9BQ35574952-ECA9D14D-A959-42CD-B9E9-DAF3F68D3938Q35610513-202D703E-E76F-458C-A434-C846854FB9F5Q36221957-2EA8A83D-1CFA-4FAF-9980-0B7882C4DB81Q36249224-EFA9710B-3BD5-429C-8007-BEA8E5AFF131Q36301463-8A355AC9-C4CB-4B3D-8D59-562B1A808DA3Q37018328-F23C77D9-F37B-4D07-B4D9-784DE8E153AAQ37414536-4B3552FA-3B25-4323-A54D-C6F44DA36C9EQ37499473-E76DC564-AB59-4928-BD6F-E8FA19EA7BC7Q37685527-517CC496-0162-42B2-B09E-E2DCD7973906Q37707119-6BDF6558-9563-439E-809D-5001053B6108Q38407822-3E8F7EFB-8A5A-4161-96D6-707A9A22BD33Q40597353-66252AD7-DAA4-4922-889C-3C0EE10C0C70Q42071811-51D65ED7-ACB6-49F7-BE06-6EF636E85664Q43988692-469490FE-733B-4A14-8D20-1981511CED1BQ45027028-BAF85C9E-4C92-4EA1-95CE-D048E525DD8FQ46862922-94E55993-42FE-41B7-B361-6A599A8E3717Q53405122-421F8CC6-6133-49AE-8125-F0753C1C6CA3Q55461722-287E29FA-91E3-46B3-9C0E-BE1B3E8B954E
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacogenetics in cancer treatment.
@en
type
label
Pharmacogenetics in cancer treatment.
@en
prefLabel
Pharmacogenetics in cancer treatment.
@en
P2093
P1476
Pharmacogenetics in cancer treatment.
@en
P2093
Innocenti F
Nagasubramanian R
P304
P356
10.1146/ANNUREV.MED.54.101601.152352
P577
2001-12-03T00:00:00Z